Agilent Technologies

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Mission Bio is a biotechnology company that specializes in developing and commercializing single-cell multi-omics solutions for precision medicine. The company's flagship product, the Tapestri Platform, is a single-cell genomics and proteogenomic characterization tool that allows researchers and clinicians to have a deeper knowledge of disease profiles by identifying disease subtypes, predicting disease progression, and understanding treatment response, and thereby accelerating discovery, development, and delivery of precision medicine. The platform also facilitates product characterization in cell therapeutics.Furthermore, the company claims that the platform's latest version launched in May 2023 captures 4x the number of cells compared to the previous chemistry. In addition, Tapestri is the only commercialized multi-omics platform capable of analyzing DNA and protein simultaneously from the same sample at single-cell resolution. It is being used by customers at research centers, pharmaceutical, and diagnostics companies to develop treatments, and, eventually, as cures for cancer.Key Customers and PartnershipsThe company has several key partnerships with pharma and biopharma companies including Amgen, Merck, Abbvie, and CRISPR Therapeutics.The company partnered with clinical diagnostic company <a href="https://sp-edge.com/updates/17651">Fulgent Genetics </a>(April 2023) to expand the accessibility of single-cell multiomics for drug development and clinical research, single-cell bioinformatics company Abiosciences (in December 2022) to co-develop bioinformatics packages for translational and clinical research applications in hematological cancers, laboratory automation solution company S2 Genomics (April 2022) to offer a single streamlined workflow for solid tumor applications from sample prep through analysis, and single-cell omics technology company SequMed (December 2021) to expand its product and services offerings into China.

RareCyte is a precision biology company that develops technologies and integrated platforms for various applications, including oncology, immuno-oncology, maternal-fetal health, and cell and gene therapy. The company's flagship product is the Orion Spatial Biology platform, which enables highly multiplexed immunofluorescence staining and imaging of tissue samples. This platform combines speed and resolution, allowing comprehensive phenotypic profiling and characterization of tissue architecture, tumor heterogeneity, and immune response on whole slides within hours.RareCyte also offers a comprehensive liquid biopsy solution, which includes the AccuCyte Sample Preparation System and CyteFinder Imaging Instrument for circulating tumor cell (CTC) and other rare cell characterization, single-cell retrieval for molecular analysis, and companion diagnostic development. The company's liquid biopsy platform has been widely adopted by academic medical centers, contract research organizations, and biopharma companies.In addition to its product offerings, RareCyte provides Precision Biology Services, including custom assay development, research and clinical trial services for rare-cell liquid biopsy assays, and tissue-based spatial profiling. Key studies conducted by RareCyte include programs for biomarker discovery and implementation, pharmaceutical mechanism of action, and drug safety. Key customers and partnershipsIn November 2022, RareCyte was selected by Wellcome Leap to participate in the USD 50 million In Utero program, aimed at reducing global stillbirth rates. The company will utilize its rare cell platform to perform novel non-invasive characterization of the placenta, generating transcriptomic data from circulating trophoblasts to model and predict gestational development.In January 2024, RareCyte announced a partnership with SOPHiA GENETICS, integrating the SOPHiA DDM Platform into its Precision Biology Services portfolio. This collaboration will enhance RareCyte's bioinformatics capabilities and support DNA sequencing of CTCs and cell-free DNA for cancer patient testing.In <a href="https://sp-edge.com/updates/28391">April 2024</a>, RareCyte partnered with to launch a new multiplex spatial biology assay service for whole-slide imaging and analysis of tissue sections. The service was enabled by RareCyte's Orion platform.

PreciseDx is an oncology diagnostics company that leverages AI for morphology-driven disease analysis. The company's core technology is an AI-powered morphology feature array (MFA) platform that analyzes histology images to provide patient-specific risk information and enhance cancer diagnosis and prognosis.&nbsp;PreciseDx's flagship product is PreciseBreast, an early-stage invasive breast cancer risk assessment tool that predicts the six-year risk of recurrence. The test uses standard H&amp;E pathology slide images and is independent of HER2, hormone receptor, and node status. The test received approval from the New York State Department of Health in&nbsp;<a href="https://www.prnewswire.com/news-releases/precisedx-receives-new-york-state-approval-for-an-ai-enabled-breast-diagnostic-301740679.html">February 2023</a>, allowing PreciseDx to begin commercial testing through its CLIA-certified laboratory.The platform aims to improve upon traditional pathology by providing objective, quantifiable data to support clinical decision-making. The technology is claimed to have shown promise in detecting early-stage Parkinson's disease with high accuracy. As of October 2024, the company was working to expand its offerings, with a prostate cancer test in development.&nbsp; &nbsp;Key customers and partnershipsIn&nbsp;<a href="https://www.prnewswire.com/news-releases/ucla-and-precisedx-announce-new-collaboration-to-advance-ai-enabled-predictions-and-risk-mitigation-for-triple-negative-breast-cancer-recurrence-302105153.html">April 2024</a>, PreciseDx announced a research partnership with UCLA's Department of Pathology and Laboratory Medicine to evaluate PreciseBreast's ability to assess recurrence risk in triple-negative breast cancer patients. The company was also collaborating with Baylor Scott &amp; White Health in Texas to further validate PreciseBreast for early-stage invasive breast cancer. Additionally, in&nbsp;<a href="https://sp-edge.com/updates/29905">May 2024</a>, the company entered a collaboration with COTA and Baptist Health South Florida to analyze the performance of PreciseBreast against traditional pathology reviews and 21-gene assay results. These partnerships aimed to expand access to PreciseDx's AI-enabled testing and validate its efficacy.

<div>
 
 Based in the UK, Biofidelity specializes in genomic analysis technologies that has developed a molecular diagnostic assay that enables the rapid detection of target DNA sequences. It offers ASPYRE, a patented molecular chemistry platform, to simplify and accelerate genomic testing. Biofidelity&rsquo;s flagship products ASPYRE-Lung and ASPYRE-Lung Reagent are lung cancer diagnostics tools that identify key biomarkers for rapid testing and developing targeted therapies.&nbsp;
 
 
 Key customers and partnerships
 
 
 Biofidelity targets a wide range of customers within the healthcare sector, including physicians, biopharmaceutical companies, and researchers, providing diagnostic solutions to the broader medical community, especially in the oncology field.&nbsp;
 
 
 In January 2024, Biofidelity collaborated with Fidelis Sustainability Distribution to make ASPYRE-Lung available to Veterans Administration (VA) customers.
 
 
 Funding and financials
 
 
 In April 2024, Biofidelity raised USD 24 million in a funding round that saw participation from investors such as Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures. The funds were expected to be used to enhance its existing technologies including ASPYRE-Lung, set up a dedicated manufacturing facility in the UK, and support clinical expansion in the US. The latest funding round brings the company's total funds raised to over USD 60 million.
 
 
 
</div>

RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. RareCyte is dedicated to bringing its innovative technology to the Life Sciences research, drug development, and diagnostic markets providing new tools to answer difficult questions related to cancer and cardiovascular disease. RareCyte's AccuCyte system is an open platform for the unbiased discovery and isolation of circulating tumor cells (CTCs) and circulating endothelial cells (CECs) from whole blood.

Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill.

Biofidelity developed a revolutionary molecular diagnostic assay that enables the rapid detection of target DNA sequences. Biofidelity’s mission is to improve and extend patients’ lives by enabling early detection of disease and better targeting of treatments with applications spanning oncology, prenatal testing, infectious disease, and organ transplant monitoring. Biofidelity was founded in 2019 and is headquartered of Cambridge, England.

HALO X-ray Technologies has been spun out of the Imaging Science Group at Nottingham Trent University and the Cranfield Forensic Institute at Cranfield University. We are developing commercially-focused OEM X-ray diffraction solutions based on novel and patented Focal Construct Technology that provides platform capability across a wide range of application areas. Their initial focus lies in the development of HALO solutions for the aviation security and the medical systems markets. We have strong ties to the aviation sector through a long and prestigious research and development programme that has previously realised novel divergent beam X-ray technology (developed and marketed through various incumbent suppliers such as 3DX-ray Ltd) and kinetic depth systems (developed and marketed through Astrophyscis Inc) as 3rd party solutions. We have a clear focus on medical systems and we are currently part of a consortium recentlly awarded an EPSRC grant on Point-of-Care High Accuracy Fracture Risk Prediction. This is an exciting project and we look forward to working with our partners in developing HALO technology for this market.

Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics. Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year. The company was founded in 2011 and headquartered in Pennsylvania, United States.

Molecular Assemblies is a San Diego-based company developing a revolutionary, enzymatic DNA synthesis technology capable of powering new products in industrial synthetic biology, personalized therapeutics, precision diagnostics, and eventually information storage, nanotechnology and more. Inspired by nature, the company’s proprietary DNA synthesis method is designed to produce long, high quality, sequence-specific DNA reliably, affordably and sustainably. With a highly experienced executive and scientific team and an expansive intellectual property portfolio, Molecular Assemblies has attracted investments from Agilent Technologies, Cavendish Impact Capital Fund, Data Collective Venture Capital, Eleven Two Capital, Genomics Investment Syndicate, Keshif Ventures, Newport Holdings, LP, and Alexandria Venture Investments.

Arima Genomics develops solutions to drive genomics discovery and human health. Their services include study design consultation, sample preparation, library preparation, bioinformatics analysis, and data interpretation. Their Hi-C technology enables researchers to build chromosome-scale assemblies. Their chromosomal loop arrangement introduces regulatory elements, resulting in altered function.

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

Nicoya is a provider of advanced analytical instruments for the biotechnology and pharmaceutical industries.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Akadeum Life Sciences develops bioseparation products to facilitate the removal of target cells from biological samples. It uses microscopic micro-bubbles to capture target cells and quickly float them to the surface of a liquid sample for removal.

MOBILion Systems is a biotechnology company that specializes in identifying and analyzing the most challenging molecules that other instruments fail to detect. Its technology focuses on biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests.MOBILion’s technology makes it easy to separate, identify, and analyze the most challenging molecules that other instruments fail to detect. The company's analytical instruments provide unprecedented sensitivity, resolution, and throughput that will fuel the development of better therapeutics, the ability to detect disease earlier, and the power to attack diseases at their roots instead of their symptoms.

Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog.

Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Their proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, their technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Their Ionic Purification System and Kits combine to provide researchers with a fast, efficient, and effective alternative for automated nucleic acid purification.

Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

NanoCellect Biomedical develops and delivers microfluidic-based solutions that are affordable, compact, and easy to use. Its expanding portfolio of instruments and consumables enables biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

LaserGen, Inc., a biotechnology company, engages in the development and commercialization of technologies for genomics application. It develops various technologies for sequencing applications. The company's products detect heritable and somatic sequence variations in the human genome for use as diagnostics tools for the management of diseases. LaserGen, Inc. was incorporated in 2002 and is based in Houston, Texas.

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 was established in 2009 and is based in Cambridge, Massachusetts, United States.

Sirific Wireless is a semiconductor company, designs and develops CMOS RF HEDGE transceivers for wireless communications market. The company offers monolithic multi-mode wireless design and digital direct conversion products; Harmony-direct upconversion transmitters; and NEXUS products, NexusRD. Its NEXUS platform combines HSDPA, WCDMA, EDGE, GPRS, and GSM with available on-chip receive diversity to deliver transceivers for multi-mode and multi-band wireless applications. The company has locations in Waterloo, Canada; Richardson, Texas; and Seoul, Korea.  Sirific Wireless Limited was founded in 2000 and is headquartered in Richardson, Texas with additional offices in the United States, Canada, and Korea.

TelASIC Communications, Inc. develops remote radio head products for WCDMA/HSDPA and WiMAX/LTE infrastructure applications. The company's products enable the transmission of high output power to deliver high data rates and coverage for mobile TV/video/audio/data-centric 3G data services. TelASIC Communications, Inc. was founded in 2001 and is based in El Segundo, California.

SAN Valley is a privately held Silicon Valley company whose mission is to deliver high reliability, cost effective, next generation storage infrastructure solutions to enterprise and service providers worldwide. SAN Valley is developing high performance end-to-end optical edge access products to address the multi-billion dollar market opportunity for delivering value-added storage connectivity into enterprise, service provider and carrier networks.

Big Bear Networks develops optical transponders and subassemblies for network operators.

Tropian, Inc. develops and provides multimode radio frequency integrated circuits and solutions for wireless devices. The company offers Timestar radio frequency integrated circuit solutions for quad-band cellular handsets; Codestar radio transceivers; and Multistar transceivers. It serves wireless device manufacturers. Tropian, Inc. was formerly known as Premier R.F., Inc.

Novera Optics develops optical access solutions. Its PON optical solutions enable equipment vendors and service providers to address fiber-to-the-building, fiber-to-the-curb extensions, multi-dwelling and multi-tenant units, remote terminals, and the central office markets. The company offers Wavelength Division Multiplexed-Passive Optical Networks (WDM-PON), an access and transport platform, which provides an architecture for access networks that enables service providers to deliver voice, data, video, and wireless services.

Axsun Technologies develops and manufactures MEMS-based micro-optical spectrometers and optical channel monitors for pharmaceutical, chemical and petrochemical, homeland security and telecom network applications. Through its expertise in micro-optics, packaging and precision engineering, Axsun has pioneered an entirely new class of high-performance, miniaturized spectroscopic instruments and devices enabling a dramatic shift from lab based measurements to on-line and at-line measurements, without compromising performance.

Spike Broadband Systems is a provider of carrier-grade and fixed wireless services.

Entridia Corporation is an Internet infrastructure company that builds revolutionary silicon and system solutions for next generation converged data and voice internets. Our products and services will empower leading edge Router System OEMs to build the Internet gateways of tomorrow.

Hitex can look back on more than 30 years of company history. After the success of the first in-circuit emulators, Hitex began marketing worldwide: the company founded a branch in Great Britain and is represented by sales partners in all other important regions of the globe.  In 1997, Hitex acquired the development tools branch of Kontron, thereby strengthening its position in the market.  Since the beginning of 2003, Hitex belongs to Infineon Technologies AG. This connection guarantees Hitex a solid and secure future and allows Hitex to maintain and extend its existing partnerships with other semiconductor manufacturers as an independent company.

Agilent provides laboratory solutions to meet the needs of analytical scientists and clinical researchers worldwide. Agilent works closely with customers to help address global trends that impact human health and the environment and to anticipate future scientific needs. Agilent's solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management.

<div> Agilent Technologies, Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. Headquartered in Santa Clara, California, Agilent was spun off from Hewlett-Packard in 1999 and has since become a premier provider of analytical instruments, software, services and solutions for laboratories worldwide. Agilent offers a comprehensive portfolio of products and services across multiple segments. Its life sciences and applied markets segment provides instruments, consumables and software for applications like liquid and gas chromatography, mass spectrometry, and spectroscopy. The diagnostics and genomics segment focuses on genomics, pathology, and nucleic acid solutions. The Agilent CrossLab segment offers laboratory services, consumables, and resource management tools. Key product lines include chromatography and mass spectrometry systems, cell analysis platforms, PCR/qPCR instruments, next-generation sequencing solutions, and laboratory software suites. In July 2024, Agilent announced the acquisition of BIOVECTRA, a contract development and manufacturing organization, for USD 925 million to expand its biopharma capabilities. The company has also been investing in digital and AI technologies, acquiring Sigsense Technologies in July 2024 to enhance its CrossLab Connect asset monitoring solution. Agilent remains focused on strategic growth areas like biopharma services. The company generated revenue of USD 6.83 billion in fiscal 2023 and employs approximately 18,000 people globally. </div>

Those who invested in Agilent Technologies (NYSE:A) five years ago are up 85%

Agilent Ventures

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

INCUMBENTS_PRESENT

<div>

 Agilent Technologies has secured approval from the US FDA for its new diagnostic tool, MAGE-A4 IHC 1F9 pharmDx. This tool is used to detect MAGE-A4 (melanoma-associated antigen A4), a type of cancer antigen commonly found in several types of cancer, including synovial sarcoma. The antigen is identified within formalin-fixed, paraffin-embedded synovial sarcoma tissue samples.
 The MAGE-A4 IHC 1F9 pharmDx is touted as the first product of its kind in the market. It assists in identifying patients who may be eligible for treatment with TECELRA, a prescribed medication approved for the treatment of advanced MAGE-A4 positive synovial sarcoma in adults of specific HLA types. These are patients who have previously undergone chemotherapy.
 
</div>

Agilent Technologies

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless